Effect analysis of compound cerebral proteolytic tablets combined with butylphthalein in treatment of cognitive dysfunction after acute cerebral infarction(ACI)
Objective To investigate the effect of compound cerebral proteolytic tablets combined with bu-tylphthalein on cognitive dysfunction after acute cerebral infarction(ACI).Methods From January 2023 to January 2024,82 patients with post-ACI cognitive dysfunction in Daxing District People's Hospital were selected and divided into random number table methods.41 patients in control group were treated with bu-tylphthalide softgel,and 41 patients in study group were treated with compound brain proteolytic tablets.Cognitive function,degree of neurological impairment,cerebral blood perfusion and serological indexes[matrix metalloproteinase-9(MMP-9),lipoprotein-associated phospholipase A2(LP-PLA2)and glial cell-derived neurotrophic factor(GDNF)]were compared between the 2 groups before the treatment and 8 weeks after the treatment.The efficacy and the incidence of adverse reactions in the 2 groups were ana-lyzed.Results The total effective rate of the treatment in study group(38/41)92.68％was higher than that in control group(31/41)75.61％(P＜0.05).After 8 weeks of the treatment,the National Institute of Health Stroke Scale(NIHSS)score in study group(5.16±1.35)was lower than that in control group(6.25±1.69),and Montreal Cognitive Assessment(MoCA)score in study group(24.07±2.59)was higher than that in control group(21.55±3.28)(P＜0.05).After 8 weeks of the treatment,the mean transit time(MTT)in study group(1.06±0.12)was lower than that in control group(1.17±0.17),while the cerebral blood volume(CBV)(1.49±0.18)×10-2 mL·g-1·min-1 and cerebral blood flow(CBF)(1.07±0.33)× 10-2 mL·g-1·min-1 in the study group were higher than those in control group(1.38±0.15)× 10-2 mL·g-1·min-1,(0.85±0.30)×10-2 mL·g-1·min-1(P＜0.05).After 8 weeks of thetreatment,MMP-9(254.25±17.22)μg/L and LP-PLA2(164.15±17.95)µg/L in study group were lower than those in control group(282.36±19.75,175.87±20.23)μg/L,while GDNF(5.76±2.29)µg/L in study group was higher than that in control group(4.33±2.15)μg/L(P＜0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(P＞0.05).Con-clusion The treatment of the patients with cognitive dysfunction after ACI with compound brain proteo-lytic tablets combined with butylphthalein can improve the efficacy,reduce the damage of nerve function and cognitive function,improve cerebral blood perfusion,and help to reduce neuroimmunoinflammatory reaction,with high drug safety.
butylphthaleincompound brain protein hydrolysate tabletsacute cerebral infarction(ACI)cognitive dysfunction
维普
万方数据
